ProcureCon Pharma US 2017

October 24-October 26, 2017

Westin Philadelphia, PA

Contact Us: 1.888.482.6012

Day 1: ProCurious The Visionaries - Elevating The Standards For Medicine’s Life-Changing Mission

07:15 AM - 08:15 AM Continental Breakfast & Registration

8:15 AM - 8:25 AM Welcome Remarks & Ice Breaker

Jenna Williams, Program Director, ProcureCon Pharma

img

Jenna Williams

Program Director
ProcureCon Pharma

08:25 AM - 08:35 AM Chairperson’s Opening Remarks

Brian Bonnell, Marketplace Director, Scientist.com

img

Brian Bonnell

Marketplace Director
Scientist.com

08:35 AM - 09:00 AM Keynote: Developing And Executing Corporate Strategy: Influential Opportunities Created Through Procurement’s Transformation Role-Playing

Ron Perry, Vice President, Global Procurement , Pfizer Global Supply & Global Operations

img

Ron Perry

Vice President, Global Procurement
Pfizer Global Supply & Global Operations

09:00 AM - 10:00 AM Multiple Perspective Case Study: Overcoming Global Silos To Keep Procurement Strategy Strong Across The World

Dapo Ajayi , Chief Procurement Officer, AstraZeneca Ed McAndrews, Head of Procurement, North America, AstraZeneca Sean Cumbie, Head of Procurement & Global Biotech, AstraZeneca


img

Dapo Ajayi

Chief Procurement Officer
AstraZeneca
img

Ed McAndrews

Head of Procurement, North America
AstraZeneca
img

Sean Cumbie

Head of Procurement & Global Biotech
AstraZeneca

10:00 AM - 10:40 AM Extended Case Study: Procurement’s Transformation In Driving Enterprise Wide Value

Ahmet Karacaoglu, Executive Director, Head of Global Strategic Sourcing, Alexion
As a CPO surveys the supply chain view, aligning leadership objectives into actionable procurement insight internationally prioritizes the allocating of attention to procurement transformation needs and the access to shared resources that can help speed drugs to market. Unite with your colleagues to implement how you can relay strategic plans to equip indirect and direct teams with the necessary tools for successful execution of both categories regionally & globally. An analytical look at Alexion’s process behind:
•The 4 Pillars of procurement value & metrics
•Gap analysis – technology, people, and process
•EC alignment


img

Ahmet Karacaoglu

Executive Director, Head of Global Strategic Sourcing
Alexion

10:40 AM - 11:20 AM Networking Break In The Solutions Zone

A lot to take in for our high intensity executive sessions. As you take a break, digest all of the activity that took place and enjoy the refreshments, feel free to connect with our speakers and solution providers as you consider how to amalgamate the procurement mindset for your organization in new age pharma and where each practitioner can activate collaboration & proficiency within your organization.

11:20 AM - 11:45 AM Case Study: The Technological Revolution and Modernizing Business Partnering

Greg Fly, Global Procurement Business Partner for the US Business Unit, Takeda Pharmaceuticals
Discover Takeda sets the foundation, builds people skills, and embraces technology to evolve Procurement’s ability to match the business need and pace, delivering sustained value. Gain a further understanding behind the value proposition of:

Modernizing Business Partnering
Evolving the approach to build solid, trust-based partnerships where Procurement has a seat at the table from day one
Helping to understand and align the various business strategies with the corporate mission. This starts with capturing the mind-set of the Procurement organization, extending to the business through vision, training, and consistent messaging.
Procurement’s Digital strategy and focusing on what really matters
View insight and efficiency through a digital lens to help to drive a more efficient and modern approach to Procurement.


img

Greg Fly

Global Procurement Business Partner for the US Business Unit
Takeda Pharmaceuticals

11:45 AM - 12:05 PM Widening the Conversation: How Collaboration Can Solve Today’s Procurement Challenges

Brian Bonnell, Marketplace Director, Scientist.com
Increased budgetary pressures, a growing supply base and increasing regulations have made the role of procurement both more challenging and more critical in the pharmaceutical industry even as many departments are continually being asked to do more with fewer and fewer resources. In this environment, procurement must evolve from purchasing and bid managers to business partners who provide solutions to these complex challenges. ProcureCon and industry consortiums exist to discuss various approaches to solve common problems, but only recently has a platform and an industry-leading provider emerged that has the ability to standardize, implement and support industry wide solutions.

img

Brian Bonnell

Marketplace Director
Scientist.com
This is a very exciting time in pharma procurement where global trends show CPOs are reshaping their roles in the C-suite. The modern procurement division has a direct impact on the growth of their companies that goes beyond cost control to become a part of the whole organizational innovation process.
Insert yourself into a deep dive of how the CPO ensures early involvement of Procurement and drives alignment with leaders to provide collaboration of Pharma’s internal operations. Aim to assess how to:

Cleverly galvanize support from your stakeholders and ensure an increasingly integral role in strategic decision making
What nuances can a CPO introduce to innovate within procurement or use procurement as an influencer to enable business innovation
Does procurement’s reporting structure need to change: Setting precedence for cross-functional engagement
Improving connections with stakeholders to locate untapped sources of value
Specifically getting your foot in the door with marketing and venture capitalist stake holders
How will a CPO be meeting the needs of the industry in 2030?


img

Marcelo B. Cunha Loureiro

Head of Procurement for Americas
GlaxoSmithKline
img

Joe Shatynski

Head of Strategic Business Services: Senior Director
Daiichi Sankyo Inc.
img

Tanya Momtahen

Vice President & Head of Global Procurement, Scientific & Clinical,
Sanofi
img

Thomas Cho

Head of Corporate Procurement: Director,
Ultragenyx
img

Brian Bonnell

Marketplace Director
Scientist.com

12:45 PM - 1:45 PM Lunch

Track A: Digitization & Risk Mitigation For Indirect Categories

1:45 PM - 2:25 PM Case Study: The Trials & Successes Medimmune’s Internal Innovation: A Journey Through E-Procurement Cross Functionality

Mark Davis, Director – MedImmune Procurement Business Partner,, AstraZeneca
AstraZeneca has partnered with Medimunne on an eProcurement platform that has recently launched in MedImmune research. This platform is an enabling tool that has integrated globally distributed strategic procurement to manage MedImmune’s large molecule services outsourcing across a spectrum of categories: pre-clinical services, toxicology, specialty laboratory development and testing, biomarker services, etc.
Utilizing the platform, Medimmune is on track to go from near zero spend under management, to roughly 80% under management in less than 6-months, while cutting engagement time by 50%. Additionally, the solution they have built integrates information taken from decisions made at the exploratory stage and makes them available to Clinical teams globally to quickly move forward with trial engagements. Through their journey, take on how to:

Assess your product lifecycle and how procurement’s needs within
Standardize and streamline the way data is captured, stored and management, to enable integration and cross-analysis
Address data duplication
Scale up your internal resources for gaining endorsement from Stakeholders

img

Mark Davis

Director – MedImmune Procurement Business Partner,
AstraZeneca

Track B: Digitization & Risk Mitigation For Direct/ Manufacturing Categories

1:45 PM - 2:25 PM Case Study: The "One Procurement" Business Case

Andrew Shigo, Global Head, Strategy Realization and Procurement Operations, Roche Pharmaceuticals
At Roche, Procurement wants to deliver higher added value to the overall organization so that we may continue to invest in innovative medicines. We also face many challenges such as patent cliffs, loss of exclusivity, and increased competition. Therefore, we are changing the way we work by creating a focused more strategic organization. Through Roche's delivery model and lessons learned discover how to
•Establish clear roles and responsibilities
•Provide one voice for suppliers
•Meet stakeholder and patient needs
•Develop a skilled, innovative Procurement workforce to deliver significant value


img

Andrew Shigo

Global Head, Strategy Realization and Procurement Operations
Roche Pharmaceuticals

Brain Storm BoardRoom Session: Call To Action For A Unified Procurement Function

1:45 PM - 2:25 PM Crystal Ball Gazing For Biotechs

Ahmet Karacaoglu, Executive Director, Head of Global Strategic Sourcing, Alexion
Those in this group will be collaborating around their biotech strategies of addressing pain points and proficiency in overall procurement development. Areas to gain insight into are:
• End Goal: Independent Growth or M&A
• Writing contracts with exit clauses in the event of an acquisition.
• Spend Focus: Total Cost; Consolidation; Compliance, Commercialization

img

Ahmet Karacaoglu

Executive Director, Head of Global Strategic Sourcing
Alexion

Track A

2:10 PM - 2:30 PM Tealbook Case Study: The Impact Of Accessible Intelligence

Stephany Lapierre, Founder & CEO, Tealbook Dana Small, Sourcing Manager, BioMarin Pharmaceutical
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates.
Session attendees will hear about:
1.The actionable value of increasing procurement’s visibility into current preferred suppliers and trusted intelligence about other potential supplier partners
2.The benefits of providing the business with instant access to credible supplier information, allowing them to participate directly in early discovery efforts
3.The advantage of increasing BioMarin’s share of knowledge and building a legacy of intelligence that will offer sustained returns
4.Ensuring alignment between the long term strategic vision and immediate supporting tactics of supplier intelligence


img

Stephany Lapierre

Founder & CEO
Tealbook
img

Dana Small

Sourcing Manager
BioMarin Pharmaceutical

Track B

2:10 PM - 2:30 PM CoreTrust Case Study: CoreTrust and the Evolving Role of Procurement

Brian J Geraghty, AVP – Business Development, CoreTrust Tripp Cates, Director of National Accounts, CoreTrust
Ask procurement professionals about their day-to-day responsibilities and they’ll undoubtedly name RFPs and contract negotiation. These are probably also the first two items on their job descriptions. Entire workdays are guided by upcoming contract renewal dates, with favoritism often given to suppliers offering an easy win. So what’s wrong with this mindset? Listen as Tripp Cates and Brian Geraghty at CoreTrust, discusses an innovative approach to delivering value by harnessing the purchasing power of aggregation.

img

Brian J Geraghty

AVP – Business Development
CoreTrust
img

Tripp Cates

Director of National Accounts
CoreTrust

General Session

2:30 PM - 3:10 PM Networking Break In The Solutions Zone

After a busy day of active listening, keynotes and networking, take control of your own event experience. This is your opportunity to network with industry peers with very similar challenges, interests and responsibilities as you discuss strategies for risk management from regional to global proactivity. We invite you to provide your insight as each roundtable is facilitated by a subject matter expert. After 30 minutes, you will be able to choose a second topic to participate in.

Table 1: Vendor Management in the Digital Age: A Move from Integration to Orchestration?
Jon Lightman, Partner & Life Science Practice Lead, ISG
Table 2: Procurement’s role in R&D – Scientists, Suppliers, Innovation & “Execution”
James Tornos, Senior Director of Global Procurement, Pfizer
Table 3: Case Study Deep Dive: The Technological Revolution And Modernizing Business Partnering
Greg Fly, Global Procurement Business Partner for the US Business Unit, Takeda Pharmaceuticals
Table 4: Roche’s "One Procurement" Business Case: The Transformation Behind The People & Process
Andrew Shigo, Global Head, Strategy Realization and Procurement Operations, Roche Pharmaceuticals
Table 5: Risk Mitigation: End-to-End Supply Chain Transformation Focusing On Sustainability And Environmental Footprint Reduction
Dr. Joseph Richardson, President & Chief Executive Officer, Professional Purchasing Partners
Table 6: The Critical Shift From Drug-Centric To Patient-Relevant


img

James Tornos

Senior Director of Global Procurement
Pfizer
img

Jon Lightman

Partner, Life Science Practice Lead
ISG
img

Greg Fly

Global Procurement Business Partner for the US Business Unit
Takeda Pharmaceuticals
img

Andrew Shigo

Global Head, Strategy Realization and Procurement Operations
Roche Pharmaceuticals
img

Joseph Richardson

President & CEO
Professional Purchasing Partners

Track A: Risk Management & Collaboration For Indirect

4:10 PM - 4:50 PM The Billion Dollar Brainstorm: From Strategy to Actions Plan:-What Does the Future of R&D Procurement Behold?

Ratan Ratnesh, Director & Head of Clinical Outsourcing, Otsuka
This 40 minute interactive-brainstorm-session will begin with a 20 minute case study and then split the audience into 3 groups to discuss the below topics. At the end of each topic’s brainstorming, the group will need to come up with one top-tip considered for implementation that will be shared at the end of this session.

1.Organizational chart and structure: Where should R&D procurement team fit compared with other outsourcing and contract management teams?
2.How can R&D procurement collaborate from discovery to clinical? How does procurement contract for ‘patient insights in approaching the patient and consideration of various needs, ie. informed consent, IRB approvals. The current challenges and solutions?
3.The vision: Implementing S2P and real time data analytics for strategic sourcing intelligence (extracting long tail enterprise data and the future of analytics looking a lot like Google)- Where would the complications lie and how would they impact R&D innovation?


img

Ratan Ratnesh

Director & Head of Clinical Outsourcing
Otsuka

Track B: Risk Management & Collaboration For Manufacturing

4:10 PM - 4:50 PM Case Study Interactive: How To Reveal Significant Cost Saving Potentials Through “Value Engineering”

Joseph Richardson, President & CEO, Professional Purchasing Partners
Ever shorter development and product lifecycles require even faster and more targeted decisions from procurement organizations. Especially under “Better, Faster, Cheaper” economic conditions. This breaking ground session will deliberate:
•How to include value engineering into your procurement and engineering team cultures
•Aligning Design and Manufacturing Engineering, for product design & development;
•Focusing on the Internal and External Supply Chain for “value”
•A Design to Cost philosophy
•Embrace Value Analysis and Concurrent Engineering to achieve maximum results, while meeting form, fit and functional requirements.
•Optimal benefits of Cross-functional team participation, from design, to retirement or refurbishment
•Effective utilization of Contractor Manufacturing Organizations (CMO).


img

Joseph Richardson

President & CEO
Professional Purchasing Partners

Track A: Risk Management & Collaboration For Indirect

4:50 PM - 5:30 PM Case Study Interactive: One Voice- Co-Creating Supplier Value Within The Cell Therapy World

Edward Karski, Senior Director – Science & Technology Outsourcing, Center of Excellence, Mallinckrodt
The point when outsourcing becomes critical to clinical stages is when both internal and external partners can understand what drives the fundamentals of strategic partnerships from early development to late stage. Discover how procurement managers can gain an alliance structure between suppliers, scientist and stakeholders through the highly successful Cooperation vs. Collaboration model:

• Establish systematic protocols for productive/trusted collaboration with scientists
• Supplier innovation to the R&D process
• Managing relationships with service providers to eliminating back door selling to help facilitate their prominence to stakeholders through procurement liasoned decision making
• How to reduce sourcing costs and cycle time
• Managing supplier diversity with continuous review
• Setting clear objectives and KPIs for your vendor’s performance throughout contract lifecycle
• Enabling efficient delivery of contracted products and services

img

Edward Karski

Senior Director – Science & Technology Outsourcing, Center of Excellence
Mallinckrodt

Track B: Risk Management & Collaboration For Manufacturing

4:50 PM - 5:30 PM Case Study: Successful Defense: Proposed Regulatory Starting Materials Changing The Game On Marketing Applications Worldwide

Valdas Jurkauskas, Senior Director of Pharmaceutical Development, Manufacturing & Quality, Corbus Pharmaceuticals
Money, quality and time are the key factors in pharmaceutical development. In reality, time controls quality: if given enough time, robust processes will be developed; quality controls the cost, robust processes will yield reproducibly high quality products. The emphasis throughout clinical development stages is on finished goods, however regulatory starting materials do not receive the same level of attention. Furthering the problem, a sponsor is quick to assume that starting materials designation used throughout clinical trial applications will be accepted in the marketing application.

Serving as critical quality attributes assessment:

  • Assess EMA critical steps for covering a broad spectrum of manufacturing processes
  • Identify the higher risk of (EMA/FDA) agencies not accepting proposed starting materials designation
  • Consider the turning points of requiring to extend GMP process upstream and how agencies view regulatory starting materials in the marketing application
  • Understand the impact of regulatory agencies agreement on starting materials designation and the risks associated with supply chain invalidation and the impact of regulatory agencies agreement on starting materials designation:
  • How do you recover from delay in approval when converting proposed starting materials into GMP process intermediates

img

Valdas Jurkauskas

Senior Director of Pharmaceutical Development, Manufacturing & Quality
Corbus Pharmaceuticals

5:30 PM - 6:30 PM Cocktail Reception

After a busy day of innovative thought, insights and collaboration, reward yourself for a productive day by joining your peers for the cocktail hour!

Live Chat Software